Columvi®▼ (glofitamab)

COLUMVI in combination with gemcitabine and oxaliplatin (GemOx) is indicated for the treatment of adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma not otherwise specified (DLBCL NOS) who are ineligible for autologous stem cell transplant (ASCT).¹

COLUMVI as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), after two or more lines of systemic therapy.¹

nil

Prescribing Information

Discover where COLUMVI can be used when treating patients with R/R DLBCL

POLIVY in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP) is indicated for the treatment of adult patients with previously untreated DLBCL.⁵
POLIVY in combination with bendamustine and rituximab is indicated for the treatment of adult patients with R/R DLBCL who are not candidates for haematopoietic stem cell transplant.⁵

POLIVY®▼ (polatuzumab vedotin) prescribing information

For the full BSH guidance, please click here: British Society for Haematology guidance on the management of relapsed or refractory diffuse large B-cell lymphoma

Mechanism of action

COLUMVI is a bispecific monoclonal antibody that binds bivalently to CD20 expressed on the surface of B cells and monovalently to CD3 in the T-cell receptor complex expressed on the surface of T cells.

By simultaneous binding to CD20 on the B cell and CD3 on the T cell, COLUMVI mediates the formation of an immunological synapse with subsequent T-cell activation and proliferation, secretion of cytokines and release of cytolytic proteins that results in the lysis of CD20-expressing B cells.¹

We are dedicated to supporting HCPs to achieve optimal patient outcomes, If you have any questions about our products, from practical matters to understanding the data, please do not hesitate to contact us.

Contact our team to discuss COLUMVI

Explore more

Content page

Watch Professor Chris Fox's overview of the STARGLO trial

Products

Content page

Review the use of COLUMVI as monotherapy for R/R DLBCL

Hematology Oncology

Content page

Explore the Roche haematology portfolio

Abbreviations:

2L, second line; 3L+, third line and beyond; ASCT, autologous stem cell transplant; BR, bendamustine + rituximab; BSH, British Society for Haematology; CAR-T, chimeric antigen receptor T-cell therapy; CIT, chemoimmunotherapy; DLBCL, diffuse large B-cell lymphoma; GemOx, gemcitabine and oxaliplatin; HCP, healthcare professional; HDT-auto, high-dose therapy with autologous stem cell transplant; HSCT, haematopoietic stem cell transplant; NICE, National Institute for Health and Care Excellence; NOS, not otherwise specified; R-GemOx, rituximab + gemcitabine and oxaliplatin; R/R, relapsed/refractory.

References:

COLUMVI Summary of Product Characteristics.
Chaganti S, et al. Br J Haematol 2025 Jun;206(6):1593–1603.
NHS. National Cancer Drugs Fund list. Available at: https://www.england.nhs.uk/publication/national-cancer drugs-fund-list/ Accessed: March 2026.
NICE. Recommendations: guidance [TA883]. NICE; 2023. Available at: https://www.nice.org.uk/guidance/ta883/chapter/1-Recomendations/ Accessed: March 2026.
POLIVY Summary of Product Characteristics.

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. You can also report via the free Yellow Card app available from the Apple App Store or Google Play Store. Adverse events should also be reported to Roche Products Ltd. Please contact Roche Drug Safety Centre by emailing welwyn.uk_dsc@roche.com or calling +44 (0)1707 367554. Adverse reactions should be reported by brand name and batch number.